Nicotinamide Riboside and Prevention of Cancer Therapy Related Cardiac Dysfunction in Breast Cancer Patients (NARNIA)
Breast Cancer, Metastatic Breast Cancer, Cancer Therapy-Related Cardiac Dysfunction
About this trial
This is an interventional prevention trial for Breast Cancer focused on measuring Breast Cancer, Anthracyclines, Niagen, Nicotinamide riboside, Nicotinamide adenine dinucleotide, Reactive oxygen species, Cardiac Dysfunction, Cardio-oncology, Cardiotoxicity, Cancer Therapy-Related Cardiac Dysfunction
Eligibility Criteria
Inclusion Criteria: Women with metastatic breast cancer (stage IV breast cancer) scheduled for anthracycline-containing chemotherapy Eastern Cooperative Oncology Group performance status 0-2 Exclusion Criteria Age <18 years Acute myocardial infarction within the last three months Participation in another pharmaceutical clinical trial of an investigational medicinal product (IMP) less than 4 weeks prior to inclusion or use of other investigational drugs within 5 half-lives of enrollment, whichever is longer Conditions that would affect the participants to comply with the study protocol as psychiatric or mental disorders, alcohol abuse or other substance abuse, suspected poor drug compliance, language barriers Life expectancy < 6 months Known allergy to any of the components in the Nicotinamide Riboside (Niagen®) tablet Contraindications or inability to undergo CMR examination
Sites / Locations
- Akershus University HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Treatment Arm
Placebo Control Arm
The patients randomised into this arm of the trial will receive 500 mg Nicotinamide Riboside b.i.d. The duration of blinded therapy will depend on the duration of anthracycline therapy, and will for some patients last for 3 months, others for 6 months.
The patients randomised into this arm of the trial will receive a matching placebo b.i.d. The duration of treatment is equivalent to the description in the treatment arm.